

# ADALIMUMAB IN PATIENTS WITH IMMUNE-MEDIATED DISEASES: EVALUATING THE TRANSITION TO THE BIOSIMILAR AND PATIENT-REPORTED OUTCOME MEASURES (PROM)

Gil-Bardaji, R; Carballo Martínez, N; Cardona Peitx G; García-Giménez, I; Garcia-Castiñeira, C; Rodríguez-González, C; Gomez-Salvany, M; Bocos-Baelo, A; Garcia-Xipell, S; Alvarez Martins, M

## Background and Importance


The introduction of **biosimilars** in treatment of immuno-mediated diseases benefits both healthcare systems and patients. Nevertheless, patient concerns about switching may **affect adherence** and long-term outcomes.

## Aim and Objectives


Assess how patients perceive the switch from reference to biosimilar or between biosimilars.

## Material and Methods

*Observational and longitudinal study*





## Results




**PAIN** 58.2% patients  
**SELF-ADMINISTRATION** 80%

**PAIN** 12,5% patients  
**SELF-ADMINISTRATION** 97,5%



**60% patients notice change in pain perception**



✓ 30% less painful and easier  
 ✓ 20% anxiety feelings decreased

## Conclusions and relevance

Switching to the biosimilar improved **PROM**, with most patients self-administering treatment, experiencing less pain, and greater satisfaction.